California Pacific Medical Ctr, San Francisco, USA
A prominent medical oncologist who is board-certified in medical oncology, Dr. Kevin Kim’s research interests are in melanoma, and targeted therapies and immunotherapy. He investigates targeted treatments based on molecular profiling of patients with metastatic melanoma.
Collaborating with Dr. Mohammed Kashani-Sabet and others in the Center for Melanoma Research and Treatment, Dr. Kim is a Principal Investigator for National Cancer Institute and industry-sponsored phase 1 and 2 clinical trials investigating the biology of genetic mutations in melanoma, as well as new combinations of targeted and immunotherapies.
With extensive experience in translational melanoma research, Dr. Kim was an integral part of the early drug development of vemurafenib and dabrafenib (both BRAF inhibitors) and trametinib (a MEK inhibitor), which are now FDA-approved drugs for patients with V600BRAF-mutant metastatic melanoma.